MediPoint: Peripheral Vascular Stents for the Lower Extremity - Global Analysis and Market Forecasts

Published: April 2013
No. of Pages: 281
   

Endovascular therapies such as stenting have been widely adopted to treat peripheral artery disease in the lower extremity. Peripheral vascular stents including bare metal, drug-eluting, covered and bioabsorbable stents are associated with improved clinical outcomes compared to balloon angioplasty alone.

The global peripheral vascular stent (PVS) market is steadily growing in the 10 countries covered in the report, including the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India.

Through GlobalData’s analysis, it is evident that currently the peripheral vascular stent market for the lower extremity is saturated with bare metal stents, followed by covered stents. However, as clinical data and appropriate reimbursement and costs are established, adoption of innovative stent technologies such as drug-eluting stents and bioabsorbable stents will increase in the future.

By the end of the forecast period, the competitive landscape will experience significant change due to the launch of bioabsorbable stents in the market, the expansion of approved indications to include infrapopliteal artery lesions and the entry of new companies such as 480 Biomedical.

Questions Answered in this Report

  • What is the current perception and adoption of vascular stents for treating indications, including the iliac, femoropopliteal and infrapopliteal arteries in the lower extremity?
  • Bare metal and covered stents have been on the market for many years; however, unmet needs still exist with respect to patency and restenosis and treating challenging lesions in the femoropopliteal and infrapopliteal arteries. How will drug-eluting and bioabsorbable stents fulfil the unmet needs of the peripheral stent market for the lower extremity?
  • What is the current perception and adoption of innovative stent platforms such as drug-eluting and bioabsorbable stents in the major markets? How will adoption of these stent technologies affect adoption of bare metal and covered stents?
  • A majority of pipeline products are drug-eluting bioabsorbable stents. As more bioabsorbable stents receive approval, how will new entrants impact the peripheral vascular stent market for the lower extremity?
  • The global PVS market for the lower extremity is forecast to steadily increase in the future. What are the key factors and opportunities that will drive the market in terms of future adoption rates leading to a mature market?
  • Regions Covered: US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India.

Market Model Features

An interactive excel forecast model based on primary research interviews and surveys with KOLs, physicians, industry participants and distributors is included in this report*. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model.

*Interactive excel forecast model only available to clients purchasing a site license or higher.

What Physicians Think

“What Physicians Think” quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.

MediPoint: Peripheral Vascular Stents for the Lower Extremity - Global Analysis and Market Forecasts

Table of Contents

1 Table of Contents 1
1.1 List of Tables 6
1.2 List of Figures 10

2 Executive Summary 12
2.1 Sales of Peripheral Vascular Stents by Region 13
2.2 Global Peripheral Vascular Stent Market 15
2.3 Unmet Needs Remain a Challenge 16
2.4 Key Players in the Global Peripheral Vascular Stent Market 16
2.5 Global Peripheral Vascular Stent Market Future Outlook 18
2.6 What Do Physicians Think? 18

3 Introduction 20
3.1 Catalyst 20
3.2 Related Reports 21
3.3 Upcoming Related Reports 21

4 Peripheral Artery Disease 22
4.1 Overview 22
4.2 Anatomy and Physiology 22
4.2.1 Peripheral Arteries of the Lower Extremity 23
4.3 Pathophysiology 25
4.4 Clinical Presentation 27
4.4.1 Symptoms of Peripheral Artery Disease 27
4.4.2 Risk Factors 28
4.4.3 Disease Classification 28
4.4.4 Diagnosis 30
4.5 Clinical Outcomes 30
4.5.1 Treatment Paradigm 30
4.5.2 Treatment Guidelines 31
4.5.3 Treatment Modalities 35
4.5.4 Endovascular Management of PAD 50
4.6 Epidemiology 56
4.6.1 Peripheral Artery Disease 56
4.7 Economic Impact 59
4.7.1 United States 59
4.7.2 EU 61
4.7.3 APAC 61
4.7.4 South America 62
4.8 Treatment Costs 62

5 Competitive Assessment 64
5.1 Overview 64
5.1.1 Peripheral Vascular Stent Market 64
5.2 Products 67
5.2.1 Bare Metal Stents 67
5.2.2 Drug-Eluting Stents 138
5.2.3 Covered Stents 144
5.2.4 Bioabsorbable Stents 154

6 Unmet Needs 156
6.1 Need for Better Clinical Outcomes in Specific Lesions 156
6.1.1 Chronic Total Occlusions 156
6.1.2 Long Lesions 156
6.1.3 Heavily-Calcified and Uncrossable Lesions 156
6.1.4 Bifurcation Lesions 156
6.2 Need to Improve Medical Therapy 157
6.3 Comparative Studies on Exercise Therapy 158
6.4 Addressing Complications of Lower-Extremity Bypass Surgery 158
6.5 Eliminating Mechanisms of Failure with Balloon Angioplasty 159
6.6 Need for Better Revascularization of the Femoropopliteal Artery 160
6.7 Difficulty in Treating the Infrapopliteal Artery 161
6.8 Lack of Clinical Data 162
6.9 Limited Designs of Low-Profile Devices 162
6.10 Addressing Challenges of Peripheral Stenting 163
6.10.1 Risk of Post-Procedural Complications 163
6.10.2 In-Stent Restenosis 165
6.10.3 Stent Fracture 166
6.10.4 Long-Term Vessel Patency 167
6.10.5 Stent Material 168
6.10.6 Stent Deployment and Deliverability 168
6.10.7 Dual Anti-Platelet Therapy 169
6.10.8 Imaging 169

7 Pipeline Products 170
7.1 Overview 170
7.2 Pipeline by Phase of Development 171
7.3 Pipeline Product Profiles – Peripheral Artery Disease 172
7.3.1 Citation Stent 172
7.3.2 MR-Enhanced Stents 173
7.3.3 ArtiStent 174
7.3.4 Hybrid Dynamic Stent 174
7.3.5 Nipro Corporation Peripheral Stent 174
7.3.6 Yukon 174
7.3.7 iCAST 176
7.3.8 Peritoneal-Lined Stents 178
7.3.9 LifeJacket Stent Graft 179
7.3.10 Esprit Bioabsorbable Vascular Scaffold (BVS) 179
7.3.11 Magic Explorer Stent 181
7.3.12 Stanza 182
7.3.13 3D Biotek Bioresorbable Stent 183
7.3.14 Archer Stent 185
7.3.15 ART Stent 186
7.3.16 Amaranth Bioabsorbable Scaffold 186
7.3.17 TephaFLEX Absorbable Peripheral Stent 186
7.3.18 Zorion Medical Stent 187
7.3.19 Summary 187

8 Clinical Trial Analysis 188
8.1 Overview 188
8.2 Trials to Watch 189
8.2.1 Abbott Vascular 189
8.2.2 Atrium Medical Corporation 190
8.2.3 Biotronik 191
8.2.4 480 Biomedical 191
8.2.5 Cook Medical 192
8.2.6 Covidien 192
8.2.7 Flexible Stenting Solutions 193
8.2.8 IDEV Technologies 194
8.2.9 Medtronic 195
8.2.10 Terumo Medical Corporation 197

9 Industry Overview 198
9.1 Procedure Trends 198
9.1.1 Factors Contributing to Rise of Peripheral Interventions 198
9.1.2 United States 198
9.1.3 EU 201
9.1.4 APAC 203
9.1.5 South America 205
9.2 Market Access 207
9.2.1 United States 207
9.2.2 EU 210
9.2.3 APAC 213
9.2.4 South America 218
9.3 Reimbursement Trends 220
9.3.1 United States 220
9.3.2 EU 222
9.3.3 APAC 223
9.3.4 South America 226
9.4 Regulatory Issues/Recalls 227
9.4.1 Regulatory Issues 227
9.4.2 Recalls 227
9.5 Mergers and Acquisitions 229
9.5.1 Abbott Laboratories 229
9.5.2 Atrium Medical Corporation 229
9.5.3 Boston Scientific Corporation 230
9.5.4 Cordis Corporation (Johnson & Johnson) 230
9.5.5 Covidien 230
9.5.6 CR Bard 230
9.5.7 Medtronic 230
9.5.8 Nexeon Stent 231
9.5.9 Terumo Corporation 231

10 Current and Future Players 232
10.1 Overview 232
10.2 Trends in Corporate Strategy 233
10.3 Company Profiles 236
10.3.1 Abbott Vascular 236
10.3.2 Amaranth Medical 238
10.3.3 Arterial Remodeling Technologies 239
10.3.4 Atrium Medical Corporation 241
10.3.5 Bard Peripheral Vascular (C.R. Bard) 243
10.3.6 Biotronik 245
10.3.7 Boston Scientific Corporation 247
10.3.8 3D Biotek 248
10.3.9 480 Biomedical 249
10.3.10 Cook Medical 251
10.3.11 Cordis Corporation (Johnson & Johnson) 253
10.3.12 CorInnova 255
10.3.13 Covidien 257
10.3.14 Cytograft Tissue Engineering 259
10.3.15 Flexible Stenting Solutions 260
10.3.16 IDEV Technologies 261
10.3.17 Kyoto Medical Planning 263
10.3.18 Medtronic 266
10.3.19 Nexeon Stent 268
10.3.20 Nipro Corporation 269
10.3.21 NovoStent Corporation 271
10.3.22 OptiMed 272
10.3.23 PeriTec Biosciences 274
10.3.24 Synergy Flow 276
10.3.25 Tepha 277
10.3.26 Terumo Corporation 279
10.3.27 TissueGen 281
10.3.28 Translumina 282
10.3.29 Vascular Concepts 285
10.3.30 Veryan Medical 286
10.3.31 VueKlar Cardiovascular 287
10.3.32 W.L. Gore & Associates 289
10.3.33 Zorion Medical 291

11 Market Drivers, Opportunities and Barriers 292
11.1 Market Drivers 292
11.1.1 Rising Prevalence of Disease 294
11.1.2 Long-Term Vessel Patency 295
11.1.3 Reducing the Risk of Restenosis 296
11.1.4 Low-Profile Stent System 296
11.1.5 Self-Expanding Nitinol Stents 298
11.1.6 Limb Amputation 298
11.1.7 Cost Considerations 299
11.1.8 Availability of Long-Term Data 299
11.1.9 Avoiding Stent-in-Stent Procedures 300
11.1.10 Reducing the Need for Dual Anti-Platelet Therapy 300
11.1.11 Accurate Stent Placement 301
11.1.12 Expected Launch of Vascular Stent Products in the US 301
11.2 Opportunities 301
11.2.1 Peripheral Stent Market 301
11.2.2 Challenges in Treating the Femoropopliteal and Infrapopliteal Arteries 303
11.2.3 Biodegradable and Bioabsorbable Stents 305
11.2.4 Target High-Risk Patients 306
11.2.5 Launch Vascular Stents in the Japanese Market 306
11.2.6 Emerging Markets 307
11.3 Market Barriers 307
11.3.1 Slow Adoption 307
11.3.2 High Selling Prices 311
11.3.3 Lack of Reimbursement 311
11.3.4 Substitutes 311

12 Market Analysis by Segment 313
12.1 Global Market Overview 313
12.2 Type of Peripheral Artery in the Lower Extremity 314
12.2.1 Iliac Artery Revascularization 314
12.2.2 Femoropopliteal Artery Revascularization 317
12.2.3 Infrapopliteal Artery Revascularization 318

13 Country Outlooks and Forecasts 319
13.1 Overview 319
13.2 United States 321
13.2.1 Overview 321
13.2.2 Market Analysis 321
13.3 France 323
13.3.1 Overview 323
13.3.2 Market Analysis 324
13.4 Germany 325
13.4.1 Overview 325
13.4.2 Market Analysis 325
13.5 Italy 328
13.5.1 Overview 328
13.5.2 Market Analysis 328
13.6 Spain 329
13.6.1 Overview 329
13.6.2 Market Analysis 330
13.7 United Kingdom 333
13.7.1 Overview 333
13.7.2 Market Analysis 333
13.8 Japan 336
13.8.1 Overview 336
13.8.2 Market Analysis 336
13.9 Brazil 338
13.9.1 Overview 338
13.9.2 Market Analysis 338
13.10 China 341
13.10.1 Overview 341
13.10.2 Market Analysis 341
13.11 India 343
13.11.1 Overview 343
13.11.2 Market Analysis 343

14 Appendix 346
14.1 Bibliography 346
14.2 Abbreviations 371
14.3 Report Methodology 374
14.3.1 Overview 374
14.3.2 Coverage 374
14.3.3 Secondary Research 374
14.3.4 Forecasting Methodology 374
14.4 Physicians and Specialists Included in this Study 377
14.5 Physician Survey 379
14.6 About the Authors 380
14.6.1 Analysts 380
14.6.2 Global Head of Healthcare 381
14.7 About MediPoint 381
14.8 About GlobalData 381
14.9 Contact Us 382
14.10 Disclaimer 382

List Of Tables

Table 1: Peripheral Vascular Stents for the Lower Extremity*, Key Metrics in the 10 Major Markets 12
Table 2: Classification Systems for Determining the Severity of PAD Symptoms 27
Table 3: Risk Factors Associated with Peripheral Artery Disease 28
Table 4: Types of Atherosclerotic Lesions 29
Table 5: TASC II Classification of Iliac Artery Lesions 32
Table 6: TASC II Classification of Femoropopliteal Artery Lesions 33
Table 7: TASC II Classification of Infrapopliteal Artery Lesions 34
Table 8: Complications of Peripheral Artery Bypass Surgery 40
Table 9: Drugs Incorporated Into Drug-Eluting Stents 43
Table 10: Types of Lesions Treated Using Atherectomy 45
Table 11: Global Prevalence of PAD in Population Age =65 Years in the Major Markets, millions, 2010-2019 56
Table 12: Direct and Indirect Healthcare Costs 59
Table 13: Healthcare Expenditures ($bn) for PAD in US and EU* 59
Table 14: US Mean Hospital Costs* for Peripheral Revascularization Procedures, 2010–2019 ($US) 62
Table 15: Global Peripheral Vascular Stent Market ($m) for Each Type of Artery in the Lower Extremity, 2012 65
Table 16: Marketed Bare Metal Stent Products 67
Table 17: Absolute Stent Family Product Portfolio 68
Table 18: Absolute Stent SWOT Analysis, 2013 70
Table 19: Astron Stent Product Portfolio 72
Table 20: Astron Stent SWOT Analysis, 2013 73
Table 21: BioMimics 3D Stent Product Portfolio 74
Table 22: BioMimics 3D Stent SWOT Analysis, 2013 75
Table 23: Complete Stent SE Product Portfolio 75
Table 24: Complete SE Stent SWOT Analysis, 2013 78
Table 25: E-Luminexx Stent Product Portfolio 79
Table 26: E-Luminexx Stent SWOT Analysis, 2013 80
Table 27: Epic Stent Product Portfolio 80
Table 28: Epic Stent SWOT Analysis, 2013 81
Table 29: FlexStent Iliac Stent System Product Portfolio 82
Table 30: FlexStent Iliac Stent System SWOT Analysis, 2013 84
Table 31: LifeStent Vascular Stent System Product Portfolio 85
Table 32: LifeStent Vascular Stent System SWOT Analysis, 2013 87
Table 33: Maris Deep Stent Product Portfolio 88
Table 34: Maris Deep Stent SWOT Analysis, 2013 89
Table 35: Maris Plus Stent Product Portfolio 90
Table 36: Maris Plus Stent SWOT Analysis, 2013 91
Table 37: Misago Stent Product Portfolio 92
Table 38: Misago Stent SWOT Analysis, 2013 94
Table 39: NovoStent Samba Stent System Product Portfolio 94
Table 40: NovoStent Samba Stent System SWOT Analysis, 2013 96
Table 41: Protégé Family of Stents Product Portfolio 97
Table 42: Protégé Family of Stents SWOT Analysis, 2013 99
Table 43: Pulsar 18 Stent Product Portfolio 100
Table 44: Pulsar 18 Stent SWOT Analysis, 2013 101
Table 45: SMART Stent Product Portfolio 102
Table 46: SMART Stent SWOT Analysis, 2013 104
Table 47: Sinus Stent Family Product Portfolio 105
Table 48: Sinus Stent Family SWOT Analysis, 2013 107
Table 49: Supera Veritas Stent Product Portfolio 108
Table 50: Supera Veritas Stent SWOT Analysis, 2013 110
Table 51: Wallstent Product Portfolio 110
Table 52: Wallstent SWOT Analysis, 2013 112
Table 53: Xpert Stent Product Portfolio 113
Table 54: Xpert Stent SWOT Analysis, 2013 115
Table 55: Zilver Stent Product Portfolio 116
Table 56: Zilver Stent SWOT Analysis, 2013 118
Table 57: Assurant Cobalt Stent Product Portfolio 119
Table 58: Assurant Cobalt Stent SWOT Analysis, 2013 121
Table 59: Chromis Deep Stent Product Portfolio 122
Table 60: Chromis Deep Stent SWOT Analysis, 2013 123
Table 61: Dynamic Stent Product Portfolio 124
Table 62: Dynamic Stent SWOT Analysis, 2013 125
Table 63: Express LD Product Portfolio 126
Table 64: Express LD SWOT Analysis, 2013 127
Table 65: IntraStent LD Stent Product Portfolio 127
Table 66: IntraStent LD Stent SWOT Analysis, 2013 128
Table 67: Omnilink Elite Stent Product Portfolio 129
Table 68: Omnilink Elite Stent SWOT Analysis, 2013 131
Table 69: ParaMount Mini GPS Product Portfolio 132
Table 70: ParaMount Mini GPS SWOT Analysis, 2013 132
Table 71: ProStar Stent Product Portfolio 133
Table 72: ProStar Stent SWOT Analysis, 2013 134
Table 73: Scuba Stent Product Portfolio 135
Table 74: Scuba Stent SWOT Analysis, 2013 136
Table 75: Visi-Pro Stent Product Portfolio 137
Table 76: Visi-Pro Stent SWOT Analysis, 2013 138
Table 77: Marketed Drug-Eluting Stent Products 138
Table 78: Xience Prime BTK Stent Product Portfolio 139
Table 79: Xience Prime BTK Stent SWOT Analysis, 2013 140
Table 80: Zilver PTX Stent Product Portfolio 141
Table 81: Zilver PTX Stent SWOT Analysis, 2013 144
Table 82: Marketed Covered Stent Products 144
Table 83: Gore Viabahn Stent Product Portfolio 145
Table 84: Gore Viabahn Stent SWOT Analysis, 2013 148
Table 85: Gore Tigris Stent Product Portfolio 149
Table 86: Gore Tigris Stent SWOT Analysis, 2013 150
Table 87: V12 Covered Stents Product Portfolio 151
Table 88: V12 Covered Stents SWOT Analysis, 2013 153
Table 89: Remedy Stent Product Portfolio 154
Table 90: Remedy Stent SWOT Analysis, 2012 155
Table 91: Global Peripheral Vascular Stent Product Pipeline 171
Table 92: Citation Stent SWOT Analysis, 2013 173
Table 93: MR-Enhanced Stents SWOT Analysis, 2013 174
Table 94: Yukon Stent SWOT Analysis, 2013 176
Table 95: iCAST Stent SWOT Analysis, 2013 178
Table 96: Peritoneal-Lined Stents SWOT Analysis, 2013 179
Table 97: Esprit BVS SWOT Analysis, 2013 181
Table 98: Magic Explorer Stent SWOT Analysis, 2013 182
Table 99: Stanza Stent SWOT Analysis, 2013 183
Table 100: 3D Biotek Bioresorbable Stent SWOT Analysis, 2013 184
Table 101: Archer Stent SWOT Analysis, 2013 185
Table 102: Medicare National Average of Inpatient Hospital Payment for Peripheral and Coronary Stenting, 2012–2013 220
Table 103: Abbott Vascular Company Profile 236
Table 104: Abbott Vascular, Marketed and Pipeline Vascular Stent Products 237
Table 105: Abbott Vascular SWOT Analysis, 2013 237
Table 106: Amaranth Medical Company Profile 238
Table 107: Amaranth Medical, Pipeline Vascular Stent Products 239
Table 108: Amaranth Medical SWOT Analysis, 2013 239
Table 109: Arterial Remodeling Technologies Company Profile 240
Table 110: Arterial Remodeling Technologies’ Pipeline Vascular Stent Products 240
Table 111: Arterial Remodeling Technologies SWOT Analysis, 2013 241
Table 112: Atrium Medical Corporation Company Profile 241
Table 113: Atrium Medical Corporation, Marketed and Pipeline Vascular Stent Products 242
Table 114: Atrium Medical Corporation SWOT Analysis, 2013 243
Table 115: Bard Peripheral Vascular (C.R. Bard) Company Profile 243
Table 116: Bard Peripheral Vascular (C.R. Bard), Marketed Stent Products 244
Table 117: Bard Peripheral Vascular (C.R. Bard) SWOT Analysis, 2013 245
Table 118: Biotronik Company Profile 245
Table 119: Marketed and Pipeline Vascular Stent Products by Biotronik 246
Table 120: Biotronik SWOT Analysis, 2013 247
Table 121: Boston Scientific Corporation Company Profile 247
Table 122: Boston Scientific Corporation, Marketed and Pipeline Vascular Stent Products 248
Table 123: Boston Scientific Corporation SWOT Analysis, 2013 248
Table 124: Company Profile – 3D Biotek 248
Table 125: 3D Biotek’s Pipeline Vascular Stent Products 249
Table 126: 3D Biotek SWOT Analysis, 2013 249
Table 127: 480 Biomedical Company Profile 250
Table 128: 480 Biomedical, Pipeline Vascular Stent Products 251
Table 129: 480 Biomedical SWOT Analysis, 2013 251
Table 130: Cook Medical Company Profile 252
Table 131: Cook Medical, Marketed Vascular Stent Products 252
Table 132: Cook Medical SWOT Analysis, 2013 252
Table 133: Cordis Corporation Company Profile 254
Table 134: Cordis Corporation’s Marketed Vascular Stent Products 254
Table 135: Cordis Corporation SWOT Analysis, 2013 255
Table 136: CorInnova Company Profile 255
Table 137: CorInnova, Pipeline Vascular Stent Products 256
Table 138: CorInnova SWOT Analysis, 2013 256
Table 139: Covidien Company Profile 257
Table 140: Covidien’s Marketed Vascular Stent Products 258
Table 141: Covidien SWOT Analysis, 2013 258
Table 142: Company Profile – Cytograft Tissue Engineering 259
Table 143: Cytograft Tissue Engineering, Pipeline Vascular Stent Products 260
Table 144: Cytograft Tissue Engineering SWOT Analysis, 2013 260
Table 145: Flexible Stenting Solutions Company Profile 260
Table 146: Flexible Stenting Solutions’ Marketed Vascular Stent Products 261
Table 147: Flexible Stenting Solutions SWOT Analysis, 2013 261
Table 148: IDEV Technologies Company Profile 261
Table 149: IDEV Technologies’ Marketed Vascular Stent Products 263
Table 150: IDEV Technologies SWOT Analysis, 2013 263
Table 151: Kyoto Medical Planning Company Profile 264
Table 152: Kyoto Medical Planning’s Marketed Vascular Stent Product 265
Table 153: Kyoto Medical Planning SWOT Analysis, 2013 265
Table 154: Medtronic Company Profile 266
Table 155: Medtronic’s Marketed and Pipeline Vascular Stent Products 267
Table 156: Medtronic SWOT Analysis, 2013 268
Table 157: Nexeon Stent Company Profile 268
Table 158: Nexeon Stent’s Pipeline Vascular Stent Product 269
Table 159: Nexeon Stent SWOT Analysis, 2013 269
Table 160: Nipro Corporation Company Profile 270
Table 161: Nipro Corporation’s Pipeline Vascular Stent Product 270
Table 162: Nipro Corporation SWOT Analysis, 2013 271
Table 163: NovoStent Corporation Company Profile 271
Table 164: NovoStent Corporation’s Marketed Vascular Stent Product 272
Table 165: NovoStent Corporation SWOT Analysis, 2013 272
Table 166: OptiMed Company Profile 273
Table 167: OptiMed’s Marketed Vascular Stent Products 274
Table 168: OptiMed SWOT Analysis, 2013 274
Table 169: Company Profile – PeriTec Biosciences 275
Table 170: PeriTec Bioscience’s Pipeline Vascular Stent Product 275
Table 171: PeriTec Biosciences SWOT Analysis, 2013 276
Table 172: Synergy Flow Company Profile 276
Table 173: Pipeline Vascular Stent Product by Synergy Flow 277
Table 174: Synergy Flow SWOT Analysis, 2013 277
Table 175: Tepha Company Profile 278
Table 176: Tepha Medical Device’s Pipeline Vascular Stent Product 278
Table 177: Tepha SWOT Analysis, 2013 279
Table 178: Terumo Corporation Company Profile 279
Table 179: Terumo Corporation’s Marketed Vascular Stent Products 280
Table 180: Terumo Corporation SWOT Analysis, 2013 281
Table 181: TissueGen Company Profile 281
Table 182: TissueGen’s Pipeline Vascular Stent Product 282
Table 183: TissueGen SWOT Analysis, 2013 282
Table 184: Translumina Company Profile 283
Table 185: Translumina’s Pipeline Vascular Stent Product 284
Table 186: Translumina SWOT Analysis, 2013 284
Table 187: Vascular Concepts Company Profile 285
Table 188: Marketed Vascular Stent Products by Vascular Concepts 285
Table 189: Vascular Concepts SWOT Analysis, 2013 286
Table 190: Company Profile – Veryan Medical 286
Table 191: Marketed Vascular Stent Products by Veryan Medical 287
Table 192: Veryan Medical SWOT Analysis, 2013 287
Table 193: VueKlar Cardiovascular Company Profile 288
Table 194: VueKlar Cardiovascular’s Pipeline Vascular Stent Product 289
Table 195: VueKlar Cardiovascular SWOT Analysis, 2013 289
Table 196: W.L. Gore & Associates Company Profile 290
Table 197: W.L. Gore & Associates’ Marketed Vascular Stent Products 290
Table 198: W.L. Gore & Associates SWOT Analysis, 2013 291
Table 199: Zorion Medical Company Profile 291
Table 200: Pipeline Vascular Stent Products by Zorion Medical 292
Table 201: Zorion Medical SWOT Analysis, 2013 292
Table 202: Global Peripheral Vascular Stent Sales ($bn) Forecast for Treating Peripheral Artery Disease in the Lower Extremity, 2010–2019 313
Table 203: Global Peripheral Vascular Stent Sales ($m) Forecast for Iliac Artery Revascularization, 2010–2019 315
Table 204: Global Peripheral Vascular Stent Sales ($m) Forecast for Femoropopliteal Artery Revascularization, 2010–2019 317
Table 205: Global Peripheral Vascular Stent Sales ($m) Forecast for Infrapopliteal Artery Revascularization, 2010–2019 319
Table 206: Peripheral Vascular Stent Sales ($m) Forecast for the United States, 2010–2019 321
Table 207: Peripheral Vascular Stent Sales ($m) Forecast for France, 2010–2019 324
Table 208: Peripheral Vascular Stent Sales ($m) Forecast for Germany, 2010–2019 325
Table 209: Peripheral Vascular Stent Sales ($m) Forecast for Italy, 2010–2019 328
Table 210: Peripheral Vascular Stent Sales ($m) Forecast for Spain, 2010–2019 330
Table 211: Peripheral Vascular Stent Sales ($m) Forecast for UK, 2010–2019 333
Table 212: Peripheral Vascular Stent Sales ($m) Forecast for Japan, 2010–2019 336
Table 213: Peripheral Vascular Stent Sales ($m) Forecast for Brazil, 2010–2019 338
Table 214: Peripheral Vascular Stent Sales ($m) Forecast for China, 2010–2019 341
Table 215: Peripheral Vascular Stent Sales ($m) Forecast for India, 2010–2019 343
Table 216: Physicians Surveyed, By Country 379

List Of Figures

Figure 1: Global Peripheral Vascular Stents Revenue ($bn), 2012 and 2019 14
Figure 2: Global Peripheral Vascular Stents Revenue ($m) by Indication in the Lower Extremity, 2010–2019 15
Figure 3: Global Peripheral Vascular Stent Market for Treating Peripheral Artery Disease in the Lower Extremity, Company Share (%), 2012 17
Figure 4: Peripheral Arteries of the Lower Extremity 23
Figure 5: Pathophysiology of Peripheral Artery Disease 25
Figure 6: Treatment Modalities – Peripheral Artery Disease 35
Figure 7: Percent of Patients with Peripheral Artery Disease Who Receive Each Therapy Option Only, Global, 2012 (n=50) 36
Figure 8: Treatment of PAD, Global, 2012 and 2018 (n=50) 39
Figure 9: Types of Stents Used to Treat Peripheral Artery Disease 42
Figure 10: Bare Metal Stent For Treating Peripheral Artery Disease 42
Figure 11: Drug-Eluting Stent for Treating Peripheral Artery Disease 43
Figure 12: Covered Stents For Treating Peripheral Artery Disease 44
Figure 13: Types of Atherectomy 47
Figure 14: Percent of Patients with Peripheral Artery Disease Who Receive Each Therapy Option Only for Iliac Artery Revascularization, Global, 2012 (n=50) 50
Figure 15: Percent of Patients with Peripheral Artery Disease Who Receive Each Therapy Option Only for Femoropopliteal Artery Revascularization, Global, 2012 (n=50) 53
Figure 16: Percent of Patients With Peripheral Artery Disease Who Receive Each Therapy Option Only for Infrapopliteal Artery Revascularization, Global, 2012 (n=50) 55
Figure 17: Global Prevalence of PAD in Population Age =65 Years in the Major Markets, millions, 2010–2019 57
Figure 18: Healthcare Expenditures ($bn) for PAD in US and EU* 60
Figure 19: US Mean Hospital Costs* for Peripheral Revascularization Procedures, 2010–2019 63
Figure 20: Global Peripheral Vascular Stent Market for Treating Peripheral Artery Disease in the Lower Extremity ($), 2012 64
Figure 21: Global Peripheral Vascular Stent Market ($m) for Each Type of Artery, 2012 66
Figure 22: Remedy Stent for Treating Peripheral Artery Disease 154
Figure 23: Percent of PAD Patients Treated with Peripheral Stenting After Failed Angioplasty in the Peripheral Arteries in the Lower Extremity, Global, 2012 and 2018 (n=50) 160
Figure 24: Percent of PAD Patients With Restenosis After Stenting in the Peripheral Arteries in the Lower Extremity, Global, 2012 (n=50) 164
Figure 25: Percent of PAD Patients with Thrombosis After Stenting in the Peripheral Arteries in the Lower Extremity, Global, 2012 (n=50) 165
Figure 26: Percent of PAD Patients Exhibiting Stent Fracture After Stenting in the Peripheral Arteries in the Lower Extremity, Global, 2012 (n=50) 166
Figure 27: Pipeline Peripheral Vascular Stent Products, 2013 170
Figure 28: Global Peripheral Vascular Stent Pipeline by Stage of Clinical Development, 2013 171
Figure 29: Population (= 65 years) of PAD Patients Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, US, 2010–2019 199
Figure 30: Population (= 65 years) of PAD Patients Receiving Stenting for the Peripheral Arteries in the Lower Extremity, US, 2010–2019 200
Figure 31: Population (= 65 years) with PAD Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, EU*, 2010–2019 201
Figure 32: Population (= 65 years) with PAD Receiving Stenting for the Peripheral Arteries in the Lower Extremity, EU*, 2010–2019 202
Figure 33: Population (= 65 years) with PAD Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, APAC*, 2010–2019 203
Figure 34: Population (= 65 years) with PAD Receiving Stenting for the Peripheral Arteries in the Lower Extremity, APAC*, 2010–2019 204
Figure 35: Population (= 65 years) with PAD Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, South America*, 2010–2019 205
Figure 36: Population (= 65 years) with PAD Receiving Stenting for the Peripheral Arteries in the Lower Extremity, South America*, 2010–2019 206
Figure 37: Medicare National Average of Outpatient Hospitalization Payment for Endovascular Procedures in the Lower Extremity, 2011–2012 221
Figure 38: Global Peripheral Vascular Stent Market for Treating Peripheral Artery Disease in the Lower Extremity, Company Share (%), 2012 232
Figure 39: Global Peripheral Vascular Stent Market for Each Type of Artery, Company Share (%), 2012 234
Figure 40: Kyoto Medical Planning, Sales Volume ($m), May 2002–May 2012 264
Figure 41: Likelihood of Physician Adoption of Each Type of Vascular Stent in the Future for Treating Peripheral Artery Disease in the Lower Extremity, Global (n=50) 302
Figure 42: Importance of Each Attribute in Adopting Vascular Stents to Treat Peripheral Artery Disease in the Lower Extremity, Global, (n=50) 303
Figure 43: Vascular Stent Market for Treating Peripheral Artery Disease in the Lower Extremity, Global 313
Figure 44: Global Peripheral Vascular Stent Market ($bn) for Treating Peripheral Artery Disease in the Lower Extremity, 2010–2019 314
Figure 45: Global Peripheral Vascular Stent Market ($m) for Iliac Artery Revascularization, 2010–2019 316
Figure 46: Global Peripheral Vascular Stent Market ($m) for Femoropopliteal Artery Revascularization, 2010–2019 318
Figure 47: Global Peripheral Vascular Stent Market ($m) for Infrapopliteal Artery Revascularization, 2010–2019 319
Figure 48: Global Peripheral Vascular Stents Revenue ($bn), 2012 and 2019 320
Figure 49: US Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 322
Figure 50: French Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 324
Figure 51: German Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 326
Figure 52: Italian Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 329
Figure 53: Spanish Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 331
Figure 54: UK Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 334
Figure 55: Japanese Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 337
Figure 56: Brazilian Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 339
Figure 57: Chinese Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 342
Figure 58: Indian Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010–2019 344

Published By: GlobalData
Product Code: GlobalData32584


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we´┐Żll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Medical Devices market as per your needs. Get the best of Medical Devices research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: